STOCK TITAN
  1. Home
  2. Sec-filings
  3. OCGN
  4. [8-K] Ocugen, Inc. Reports Material Event

Ocugen (NASDAQ: OCGN) shifts CMO duties to interim leader

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Ocugen, Inc. reported a leadership change in its medical organization. Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from the company as Chief Medical Officer. On the same date, Ocugen appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer, ensuring continuity of senior medical leadership while the company evaluates longer-term plans for the role.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Effective date of CMO separation May 8, 2026 Separation of Huma Qamar, M.D., as Chief Medical Officer
Effective date of interim CMO appointment May 8, 2026 Appointment of Mohamed Genead, M.D., M.Sc., as Acting/Interim CMO
Commission File Number 001-36751 Ocugen SEC registration reference
Company address ZIP code 19355 Malvern, Pennsylvania principal executive offices
Emerging growth company regulatory
"Emerging growth company Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02 regulatory
"Item 5.02. Departure of Directors or Certain Officers;"
Item 8.01 regulatory
"Item 8.01. Other Events. Effective May 8, 2026, the Company appointed"
Item 8.01 is the section of a company’s current report to regulators used to disclose “other events” that are important but don’t fit into the report’s specific boxes. Think of it as a public bulletin board where a company posts unexpected or miscellaneous developments—legal updates, product news, or management changes—that investors need to know because they can change how the market values the company or influence investment decisions.
Chief Medical Officer financial
"separated from Ocugen, Inc. as its Chief Medical Officer."
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
Acting/Interim Chief Medical Officer financial
"appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer."
Understanding 8-K Material Events →
false 0001372299 0001372299 2026-05-08 2026-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 8, 2026

 

OCUGEN, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36751   04-3522315
(State or other jurisdiction
of incorporation)		   (Commission File
Number)		   (IRS Employer
Identification No.)

 

11 Great Valley Parkway

Malvern, Pennsylvania

  19355
(Address of principal executive offices)   (Zip Code)

 

(484) 328-4701

Registrant’s telephone number, including area code: 

 

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, par value $0.01 per share   OCGN  

The Nasdaq Stock Market LLC

(The Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.

 

Item 8.01. Other Events.

 

Effective May 8, 2026, the Company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer.

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    OCUGEN, INC.
     
Date: May 14, 2026 By: /s/ Shankar Musunuri
    Name: Shankar Musunuri
    Title: Chairman, Chief Executive Officer, & Co-Founder

 

3

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did Ocugen (OCGN) disclose in this 8-K filing?

Ocugen disclosed a change in its top medical leadership. Huma Qamar, M.D., separated from the company as Chief Medical Officer, and Mohamed Genead, M.D., M.Sc., was appointed Acting/Interim Chief Medical Officer effective May 8, 2026.

When did Ocugen’s Chief Medical Officer transition take effect?

The transition took effect on May 8, 2026. On that date, Huma Qamar, M.D., ended her role as Chief Medical Officer and Ocugen appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer to immediately assume responsibilities.

Who left the Chief Medical Officer role at Ocugen (OCGN)?

Huma Qamar, M.D., MPH, CMI, separated from Ocugen as Chief Medical Officer effective May 8, 2026. The filing states only that she separated from the company in this role, without providing further detail on the circumstances of her departure.

Who is Ocugen’s new Acting/Interim Chief Medical Officer?

Ocugen appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer effective May 8, 2026. He assumes the senior medical leadership role on an interim basis following the separation of former Chief Medical Officer Huma Qamar, M.D.

Which 8-K items did Ocugen (OCGN) reference in this report?

The report references Item 5.02 and Item 8.01. Item 5.02 covers the departure of a principal officer, while Item 8.01 is used to disclose other events, including the appointment of Mohamed Genead, M.D., as Acting/Interim Chief Medical Officer.

Filing Exhibits & Attachments

3 documents

Other Documents